BRIEF published on 05/21/2026 at 22:05, 3 months 17 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva Lanifibranor MASH Treatment Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 3 months 17 days ago Inventiva à la 2026 Jefferies Global Healthcare Conference Biopharmaceutique Inventiva Conférence Jefferies MASH Lanifibranor
PRESS RELEASE published on 05/21/2026 at 22:00, 3 months 17 days ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Inventiva to present at 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain to speak on June 3, 2026, about MASH therapies Clinical-Stage Biopharmaceutical Inventiva Lanifibranor 2026 Jefferies Conference MASH Therapies
PRESS RELEASE published on 05/21/2026 at 22:00, 3 months 17 days ago Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference Inventiva présentera lors de la 2026 Jefferies Global Healthcare Conference à New York City son traitement oral pour la stéatohépatite. Détails de la présentation le 3 juin 2026 Inventiva Lanifibranor Stéatohépatite 2026 Jefferies Global Healthcare Conference Traitement Oral
BRIEF published on 05/13/2026 at 08:35, 3 months 25 days ago Inventiva présente ses recherches sur le lanifibranor au EASL Congress 2026 Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 3 months 25 days ago Inventiva présentera des résumés au congrès EASL 2026 Recherche Biopharmaceutique Inventive Lanifibranor Traitement MASH Congrès EASL 2026
BRIEF published on 05/13/2026 at 08:35, 3 months 25 days ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 3 months 25 days ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 3 months 25 days ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 3 months 25 days ago Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026 Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026. Découvrez les détails des présentations et la présence de la société au congrès Biopharmaceutique Inventiva MASH Lanifibranor EASL Congress 2026
Published on 09/08/2026 at 01:45, 4 hours 12 minutes ago Tunkillia Environmental Scoping Report Approved
Published on 09/05/2026 at 04:05, 3 days 1 hour ago Pelican AI Corp. Announces Proposed Share Issuances and Litigation Update
Published on 09/04/2026 at 23:30, 3 days 6 hours ago FutureGen Industries Announces Shares for Debt Settlement
Published on 09/04/2026 at 23:00, 3 days 6 hours ago Golden Minerals Announces Management Change and Argentine Project Update
Published on 09/04/2026 at 22:30, 3 days 7 hours ago Panther Minerals Closes Brokered Private Placement of $3,000,000
Published on 09/07/2026 at 19:19, 10 hours 38 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Sales and Adjusted EBIT in Q2 2026/27 above prior-year level – FY outlook maintained
Published on 09/07/2026 at 19:00, 10 hours 57 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 31 août 2026 au 4 septembre 2026
Published on 09/07/2026 at 18:42, 11 hours 15 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/07/2026 at 18:00, 11 hours 57 minutes ago E-PANGO: e-Pango organise un webinaire avec ses actionnaires
Published on 09/07/2026 at 17:45, 12 hours 12 minutes ago VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 09/07/2026 at 19:00, 10 hours 57 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 4 septembre 2026
Published on 09/07/2026 at 19:00, 10 hours 57 minutes ago Information concerning the total number of voting rights and shares in the share capital as of September 4, 2026
Published on 09/07/2026 at 18:05, 11 hours 52 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/08/2026
Published on 09/07/2026 at 18:05, 11 hours 52 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/08/2026
